Hospital
The Bellevue Hospital
The Bellevue Hospital was paid $8.20M by Medicaid between Jan 2018 and Dec 2024, across 189 billing codes. Its largest line is 99285, emergency room visit (most serious) — 17% of everything it billed.
33Billing provider infoTHE BELLEVUE HOSPITAL
BELLEVUE, OH 44811
BELLEVUE, OH 44811
33aNPI1134161623assigned 06/11/2006
33bProvider typeMedicare Defined Swing Bed Hospital Unit
28Total paid$8.20M
24GClaims224,910
24DCodes billed189
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 17,452 | $533K | |
| 2019 | 15,300 | $472K | |
| 2020 | 12,444 | $650K | |
| 2021 | 19,401 | $916K | |
| 2022 | 22,286 | $1.03M | |
| 2023 | 84,364 | $2.78M | |
| 2024incomplete | 53,663 | $1.82M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 17% | 11,163 | 9,577 | $1.40M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 10,435 | 9,230 | $1.20M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 10,083 | 9,166 | $1.09M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 7.0% | 3,565 | 3,164 | $570K |
| 96361 | Intravenous infusion, hydration; each additional hour | 5.4% | 1,366 | 890 | $446K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 3.4% | 2,349 | 1,992 | $280K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.0% | 3,157 | 2,589 | $246K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.9% | 945 | 731 | $237K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.5% | 747 | 554 | $201K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.4% | 1,165 | 741 | $197K |
| 59025 | Fetal non-stress test | 2.0% | 1,122 | 656 | $164K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.8% | 543 | 416 | $148K |
177 more codes
| G0378 | Hospital observation service, per hour | 1.5% | 1,557 | $123K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.3% | 1,587 | $107K |
| 80053 | Comprehensive metabolic panel | 1.1% | 11,382 | $94K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.1% | 772 | $91K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 1.0% | 461 | $84K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.0% | 373 | $83K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 552 | $73K |
| 76818 | <1% | 513 | $63K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,454 | $60K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 19,392 | $58K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 361 | $56K |
| 73630 | <1% | 1,280 | $53K | |
| 88143 | <1% | 2,498 | $50K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,158 | $50K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 925 | $50K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,829 | $48K |
| 36415 | Collection of venous blood by venipuncture | <1% | 25,000 | $45K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,419 | $39K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 573 | $38K |
| 84702 | <1% | 2,153 | $35K | |
| 76830 | Ultrasound, transvaginal | <1% | 699 | $32K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,070 | $32K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 168 | $32K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 274 | $31K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,918 | $29K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,851 | $23K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,885 | $22K |
| 73610 | <1% | 667 | $22K | |
| 80061 | Lipid panel | <1% | 1,382 | $22K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 166 | $20K |
| 86850 | <1% | 783 | $19K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 150 | $16K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,101 | $16K |
| 87480 | <1% | 624 | $15K | |
| 87800 | <1% | 529 | $15K | |
| 84439 | <1% | 733 | $15K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 254 | $14K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 900 | $14K |
| J3490 | Unclassified drugs | <1% | 2,878 | $13K |
| 93971 | <1% | 211 | $13K | |
| 86900 | <1% | 908 | $12K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 120 | $12K |
| 84436 | <1% | 963 | $11K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 482 | $11K |
| 87660 | <1% | 624 | $10K | |
| 86803 | <1% | 457 | $9K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,709 | $9K |
| 87150 | <1% | 569 | $8K | |
| 86901 | <1% | 908 | $8K | |
| 83525 | <1% | 340 | $7K | |
| 87510 | <1% | 624 | $7K | |
| 87081 | <1% | 647 | $7K | |
| 84481 | <1% | 519 | $7K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 80 | $7K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 466 | $6K |
| 83540 | <1% | 632 | $6K | |
| 87340 | <1% | 296 | $6K | |
| 74018 | <1% | 193 | $6K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 70 | $6K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,110 | $6K |
| 84479 | <1% | 296 | $6K | |
| 97161 | <1% | 114 | $5K | |
| 80076 | <1% | 484 | $5K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,068 | $5K |
| 86140 | <1% | 531 | $5K | |
| 94667 | <1% | 31 | $5K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 112 | $4K |
| 80320 | <1% | 558 | $4K | |
| 81001 | <1% | 3,368 | $4K | |
| 84484 | <1% | 2,281 | $4K | |
| 87070 | <1% | 1,081 | $4K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,730 | $4K |
| 86762 | <1% | 210 | $3K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 196 | $3K |
| 0001A | <1% | 106 | $3K | |
| 85610 | <1% | 1,274 | $3K | |
| 86592 | <1% | 256 | $3K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 467 | $3K |
| 82607 | <1% | 158 | $3K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 28 | $3K |
| 0002A | <1% | 86 | $3K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 190 | $3K |
| 87186 | <1% | 672 | $2K | |
| 82728 | <1% | 171 | $2K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 1,220 | $2K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 12 | $2K |
| 83880 | <1% | 557 | $2K | |
| 85730 | <1% | 804 | $2K | |
| 83735 | <1% | 731 | $2K | |
| 85027 | <1% | 523 | $2K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 302 | $2K |
| 87420 | <1% | 283 | $2K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,174 | $2K |
| 86593 | <1% | 171 | $2K | |
| 81003 | <1% | 1,923 | $2K | |
| 73030 | <1% | 107 | $2K | |
| 82950 | <1% | 108 | $2K | |
| 86703 | <1% | 87 | $1K | |
| 85652 | <1% | 451 | $1K | |
| 84703 | <1% | 2,129 | $1K | |
| 74022 | <1% | 140 | $1K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,452 | $1K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 144 | $1K |
| 73564 | <1% | 98 | $1K | |
| 72100 | <1% | 64 | $1K | |
| 83605 | <1% | 1,348 | $1K | |
| 96367 | <1% | 40 | $1K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,881 | $1K |
| 82553 | <1% | 307 | $1K | |
| 96376 | <1% | 841 | $1K | |
| 73110 | <1% | 30 | $994.90 | |
| 87077 | <1% | 250 | $956.47 | |
| 83690 | <1% | 1,691 | $885.02 | |
| 82570 | <1% | 91 | $765.27 | |
| 83874 | <1% | 293 | $683.68 | |
| 87040 | <1% | 596 | $609.59 | |
| 86706 | <1% | 30 | $512.02 | |
| 73130 | <1% | 28 | $485.90 | |
| 82105 | <1% | 23 | $481.46 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 118 | $455.38 |
| 82948 | <1% | 524 | $443.84 | |
| 85007 | <1% | 183 | $442.13 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 396 | $397.35 |
| 82150 | <1% | 256 | $385.39 | |
| 82550 | <1% | 349 | $362.03 | |
| 90715 | <1% | 22 | $359.54 | |
| 83001 | <1% | 16 | $323.36 | |
| 82043 | <1% | 53 | $308.12 | |
| 83002 | <1% | 16 | $303.15 | |
| 85378 | <1% | 408 | $250.55 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,417 | $234.67 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 761 | $185.03 |
| 84550 | <1% | 13 | $154.35 | |
| 73562 | <1% | 13 | $139.24 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 427 | $115.18 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 922 | $94.11 |
| 81015 | <1% | 69 | $85.43 | |
| 84100 | <1% | 16 | $56.22 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,459 | $36.94 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 294 | $33.77 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 19 | $32.02 |
| 80179 | <1% | 247 | $31.28 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,234 | $29.51 |
| 80329 | <1% | 211 | $28.59 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 200 | $23.67 |
| 83550 | <1% | 12 | $21.09 | |
| J1094 | Injection, dexamethasone acetate, 1 mg | <1% | 212 | $19.88 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 569 | $19.22 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 111 | $14.01 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 567 | $13.13 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,984 | $10.26 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 898 | $10.09 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 558 | $9.74 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 180 | $6.78 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 106 | $4.06 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 73 | $3.15 |
| J2704 | Injection, propofol, 10 mg | <1% | 694 | $2.13 |
| 91300 | <1% | 192 | $1.61 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 444 | $1.40 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 226 | $1.02 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 160 | $0.85 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 103 | $0.57 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 28 | $0.23 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 20 | $0.09 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 287 | $0.00 |
| 00840 | 0% | 52 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 18 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 35 | $0.00 |
| 82800 | 0% | 19 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 30 | $0.00 |
| 36416 | 0% | 16 | $0.00 | |
| 94761 | 0% | 212 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 143 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 13 | $0.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 22 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 27 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBUIT, TIM (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Bellevue Professional Services, INC. | Bellevue, OH | $2.73M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.